Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Q1 FY23 Earnings Presentation
17 slides from Health X Platform's earnings presentation, Sep 5, 2022
Slide 1: Intimation under Regulation 30 of SEBI Listing Regulations
^^d^hEZsEdhZ^>/D/d njŝŵŐĂŶũ,ŽƵƐĞ͕ϮŶĚĨůŽŽƌ͕ ϳďĂŶŝŶĚƌĂEĂƚŚdŚĂŬƵƌ^ĂƌĂŶŝ;&ŽƌŵĞƌůLJĂŵĂĐ^ƚƌĞĞƚͿ͕ <ŽůŬĂƚĂʹϳϬϬϬϭϳ͕/ŶĚŝĂ͘dĞů͗нϵϭϯϯϮϮϴϮϵϯϯϬ͖&Ădž͗нϵϭϯϯϮϮϴϮϵϯϯϱ ŵĂŝů͗ŝŶĨŽΛƐĂƐƚĂƐƵŶĚĂƌ͘ĐŽŵ͖tĞďƐŝƚĞ͗ǁǁǁ͘ƐĂƐƚĂƐƵŶĚĂƌǀĞŶƚƵƌĞƐ͘ĐŽŵ /E͗>ϲϱϵϵϯtϭϵϴϵW>ϬϰϳϬϬϮ ĂƚĞ͗ϬϱͲϬϵͲϮϬϮϮ dŽ dŽ dŚĞ'ĞŶĞƌĂůDĂŶĂŐĞƌ dŚĞDĂŶĂŐĞƌ ĞƉĂƌƚŵĞŶƚŽĨŽƌƉŽƌĂƚĞ
Slide 2: Investor Presentation September 2022
Investor Presentation September 2022
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Key Financial Highlights
Key Financial Highlights Revenue from Operations Gross Profit 7.5% 6.4% +13.0% -3.9% 191.6 12.7 12.2 169.6 Q1FY22 Q1FY23 Q1FY22 Q1FY23 Gross Profit Revenue Gross Profit for Q1FY23 stood at Rs. 12.2 crs. Revenue for Q1FY23 stood at Rs. 191.6 crs as compared to Rs. Gross Profit margins were impa
Slide 5: Q1 FY23 Consolidated Profit & Loss Statement
Q1 FY23 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q1 FY23 Q1 FY22 Y-o-Y Q4 FY22 Q-o-Q FY22 FY21 Y-o-Y Revenue from Operations 191.6 169.6 13.0% 157.6 21.6% 623.0 540.0 15.4% Cost of Materials Consumed 179.4 156.9 148.0 582.5 492.5 Gross Profit 12.2 12.7 (3.9%) 9.6 27.1% 40.5 47.5 GP
Slide 6: Management Comments
Management Comments Commenting on the results and performance for Q1FY23, Mr. B.L. Mittal, Founder & Executive Chairman said “We are pleased to report that our revenue has grown to Rs. 191.6 crore for the first quarter of FY 2022-23. Our expansion includes starting of operation from our new warehous
Slide 7: Future Macro Strategy: Focus & Growth
Future Macro Strategy Macro Strategy Focus & Growth ‘Digital Platform of Healthcare’ Pharmacy Wellness Diagnostic Develop Leverage Deliver 3T 2C 3C Team Cash Flow Customer Base Technology Customer Experience Capital Trust Community Wellbeing Health & Happiness
Slide 8: Micro Strategy: B2C Platform, B2B Platform, Genu Path Labs
Micro Strategy Micro Strategy B2C Platform B2B Platform Genu Path Labs • Expand & Grow network of Seller • Expand – PAN India, Accelerate • Expand Diagnostic Network in Eastern Pharmacies – PAN India growth India • Expand fulfilment capabilities – • Leverage scale to Maximise • Leverage consumer bas
Slide 9: Historical Financial Highlights
Historical Financial Highlights
Slide 10: FY22 Financial Highlights
FY22 Financial Highlights Rs. In Crs Revenue Revenue from from Operations Operations Gross Profit Q4 4.5% 8.8% 6.5% Q3 62% Q2 137% 622 Q1 48 540 158 +20% 11 41 132 385 10 141 +5% 12 116 134 8 155 +11% 17 13 103 140 10 5 92 4 134 169 +26% 5 12 13 74 3 FY20 FY21 FY22 FY20 FY21 FY22 Gross Profit Revenu
Slide 11: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Revenue from Operations 623.0 540.0 384.0 215.6 148.3 Cost of Materials Consumed 582.5 492.5 366.9 199.5 140.4 Gross Profit 40.5 47.5 17.1 16.1 7.9 GP % 6.5% 8.8% 4.5% 7.5% 5.3% Employee Benefits
Slide 12: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Assets (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 57.2 57.3 60.2 62.7 64.8 Other Equity 1175.7 197.6 214.4 168.6 171.3
Slide 13: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Cash Flow from Operating Activities Profit before Tax 1,109.5 (16.4) (57.6) (41.8) (12.4) Adjustment for Non-Operating Items 1,151.0 (3.2) 4.8 7.8 5.4 Operating Profit before Working Capital Changes
Slide 14: Backed by Globally Acclaimed Investors
Backed by Globally Acclaimed Investors At Business Level S.R. Batliboi & Co. LLP (a member firm of EY) Mitsubishi Corporation Auditors Investors At Consolidated Level J K V S & CO Rohto Pharmaceutical Co., Ltd. Health & Happiness
Slide 15: Experienced Board of Directors
Experienced Board of Directors FCA, FCS and FCM by education and has an experience of FCA by education and is a seasoned entrepreneur with more than 20 years working as an entrepreneur and a more than 20 years of demonstrated experience in social worker. scaling businesses from scratch. Areas
Slide 16: Join Us For Prayers
Join Us For Prayers Health & Happiness
Slide 17: Thank You
Company: Thank You Sastasundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh – Company Secretary Email Id : p_singh@sastasundar.com www.sastasundarventures.com Investor Relations Partner: Orient Capital (a division of Link Group) Payal Dave Rasika Sawant payal.dave@linkintime.co.in ra